Showing 6391-6400 of 7756 results for "".
- Katie Cheng Is Cynosure's New CMOhttps://practicaldermatology.com/news/katie-cheng-is-cynosures-new-cmo/2460646/Katie Cheng is Cynosure’s new Chief Marketing Officer. "Katie's proven track record of consumer and professional marketing strategy and execution is one of the many reasons we are eager to have Katie join our team," says Cynosure CEO Todd Tillemans, i
- Soliton Appoints Sean J. Shapiro as Vice President of Saleshttps://practicaldermatology.com/news/soliton-appoints-sean-j-shapiro-as-vice-president-of-sales/2460643/Sean J. Shapiro is Soliton, Inc’s New Vice President of Sales, effective January 1, 2021. "We are very excited to have Sean join our team during this pivotal time for the company as we anticipate clearance of our 510(k) application for cellulite reduction duri
- Aerolase Introduces Skin of Color Forumhttps://practicaldermatology.com/news/aerolase-introduces-skin-of-color-forum/2460639/Aerolase Corp. is launching a Skin of Color Forum (SOCF). "This Forum is much needed and transformative. It's been rewarding to work alongside Aerolase to shape its leadership in advancing skin of color dermatology," sa
- For Upper Facial Lines, DaxibotulinumtoxinA Succeeds in Phase 2https://practicaldermatology.com/news/for-upper-facial-lines-daxibotulinumtoxina-succeeds-in-phase-2/2460637/Topline efficacy and safety results from the phase 2 multicenter, open-label study of Revance's investigational drug candidate DaxibotulinumtoxinA for Injection for the combined treatment of upper facial lines, show high levels of patient satisfaction. The 36-week study enrolled 48
- Hydrafacial To Go Public After $1.1 Billion Dealhttps://practicaldermatology.com/news/hydrafacial-to-go-public-after-11-billion-deal/2460634/The HydraFacialCompany and Vesper Healthcare, a special purpose acquisition company (SPAC) co-founded by Brent Saunders, former CEO of Allergan, have entered into a definitive merger agreement. Under the terms of the agreement, HydraFacial and Vesper Healthcare will combine, and HydraFa
- Almirall's Klisyri Gets FDA Approval for AKshttps://practicaldermatology.com/news/almiralls-klisyri-gets-fda-approval-for-aks/2460632/Almirall is expected to launch Klisyri® (tirbanibulin) for the topical treatment of actinic keratosis (AK) of the face or scalp in the first quarter of 2021, after receiving FDA approval this week. Klisyri® is a novel, topic
- Evelo's AD Candidate Meets Phase 1b Endpointshttps://practicaldermatology.com/news/evelos-ad-candidate-meets-phase-1b-endpoints/2460631/Evelo Biosciences, Inc.’s investigational atopic dermatitis treatment EDP1815 was well tolerated with no serious adverse events in a phase 1b clinical trial. According to the company, the oral drug candidate studied in 23 evaluable subjects with
- AbbVie’s Rinvoq Performs Well in Head-to-Head Phase 3b AD Studyhttps://practicaldermatology.com/news/abbvies-rinvoq-performs-well-in-head-to-head-phase3b-ad-study/2460630/Topline results from the phase 3b “Heads Up” study show that a greater proportion of subjects treated with AbbVie’s Rinvoq (upadacitinib 30mg, once daily) achieved at least a 75 percent improvement in the Eczema Area Severity Index (EASI 75) at week 16, compared to dupilumab (30
- Are Sunscreens Overstating Their SPF?https://practicaldermatology.com/news/are-sunscreens-overstating-their-spf/2460629/One out of 12 sunscreens worldwide are likely overstating their sun protection factor, according to research from What’s In My Jar, a London-based AI-powered skincare startup. Using machine learning, What’s In My Jar analyzed formulas of 1,205 sunscreen products in thei
- Colleen Goggins Joins ZO Skin Health's Board Of Directorshttps://practicaldermatology.com/news/colleen-goggins-joins-zo-skin-healths-board-of-directors-following-majority-investment-by-blackstone/2460624/Colleen Goggins is joining ZO Skin Health’s board of directors. This follows the recent acquisition of a majority stake in the business in October by funds managed by Blackstone Tactical Opportunities. As a partner and counsellor to a large variety of bu